Vyne Therapeutics Inc ( (VYNE) ) has released its Q1 earnings. Here is a breakdown of the information Vyne Therapeutics Inc presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops therapies for chronic inflammatory and immune-mediated conditions, focusing on unmet medical needs with its proprietary BET inhibitors.
In its first quarter of 2025, VYNE Therapeutics reported a net loss of $8.6 million, with revenues totaling $0.2 million. The company is advancing its Phase 2b trial for repibresib gel, targeting vitiligo, with results expected mid-year, while addressing a clinical hold on its VYN202 psoriasis trial.
Key financial highlights include a cash position of $50.3 million, expected to sustain operations into the second half of 2026. Research and development expenses increased to $6.1 million, driven by ongoing trials, while general and administrative expenses decreased slightly to $3.3 million.
Looking ahead, VYNE Therapeutics remains focused on progressing its clinical trials and resolving the clinical hold on VYN202, with a strategic emphasis on addressing significant unmet needs in dermatology and immunology.